The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).

Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months

Inclusion Criteria:

• Be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender.
• For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old.
• Be cycloplegic autorefraction spherical component -0.50 D to -6.00D, cylinder no more than -2.00D, and with a spherical equivalent greater than or equal to -6.00D.
• Be accompanied by parents/guardians who can read and comprehend give informed consent as demonstrated by signing a record of informed consent.
• Be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
• Have ocular health findings considered to be "normal".
• Be correctable to at least 6/9.5 (20/30) or better in each eye with spectacles.
• Be willing to wear the spectacles provided by the investigators for all waking hours.

Exclusion Criteria:

• A known allergy to, or a history of intolerance to cyclopentolate or topical anesthetics.
• Had strabismus and/or amblyopia.
• Cylinder more than -2.00D
• Anisometropia greater than 1.50D spherical equivalent
• Had previous eye surgery (including strabismus surgery).
• Any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes.
• Had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids.
• Current orthoptic treatment or vision training.
• Any anatomical, skin or other condition that would impact on the wearing of spectacles.
• Use of or need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
• Currently enrolled in another clinical trial.
• No previous myopia management intervention or treatment.

Children aged between 6-12 years old from Spain, Portugal and the United Kingdom